We treated 11 children with vitamin D-resistant rickets with a phosphate mixture either alone (1.2 to 3.6 g per day) or combined with ergocalciferol (vitamin D2, to 50 x 103 IU per day) or with calcitriol (1,25-dihydroxyvitamin D3, 0.25 to 1 microgram per day). Serum calcitriol concentrations were normal in all patients. Calcitriol therapy circulating levels of the hormone to values above normal and increased intestinal phosphate absorption. In some patients this regimen decreased the need for phosphate supplements. None of the treatment regimens corrected the renal phosphate leak. Radiologic studies and bone histomorphometric analyses showed that phosphate (alone or with ergocalciferol) induced the mineralization of the growth plate but not of the endosteal bone surface. Combined calcitriol and phosphate therapy for a total of 2850 patient-days greatly improved the mineralization of trabecular bone. Short-term episodes of hypercalcemia were easily controlled by changes in calcitriol dosage. The data indicate that the combined calcitriol and phosphate regimen is useful in the treatment of vitamin D-resistent rickets.
This article has been cited by other articles:
Jehan, F., Gaucher, C., Nguyen, T. M., Walrant-Debray, O., Lahlou, N., Sinding, C., Dechaux, M., Garabedian, M.
(2008). Vitamin D Receptor Genotype in Hypophosphatemic Rickets as a Predictor of Growth and Response to Treatment. J. Clin. Endocrinol. Metab.
93: 4672-4682
[Abstract][Full Text]
Palmada, M., Dieter, M., Speil, A., Bohmer, C., Mack, A. F., Wagner, H. J., Klingel, K., Kandolf, R., Murer, H., Biber, J., Closs, E. I., Lang, F.
(2004). Regulation of intestinal phosphate cotransporter NaPi IIb by ubiquitin ligase Nedd4-2 and by serum- and glucocorticoid-dependent kinase 1. Am. J. Physiol. Gastrointest. Liver Physiol.
287: G143-G150
[Abstract][Full Text]
Savio, R. M., Gosnell, J. E., Posen, S., Reeve, T. S., Delbridge, L. W.
(2004). Parathyroidectomy for Tertiary Hyperparathyroidism Associated With X-linked Dominant Hypophosphatemic Rickets. Arch Surg
139: 218-222
[Abstract][Full Text]
Makitie, O., Doria, A., Kooh, S. W., Cole, W. G., Daneman, A., Sochett, E.
(2003). Early Treatment Improves Growth and Biochemical and Radiographic Outcome in X-Linked Hypophosphatemic Rickets. J. Clin. Endocrinol. Metab.
88: 3591-3597
[Abstract][Full Text]
Ecarot, B., Desbarats, M.
(1999). 1,25-(OH)2D3 Down-Regulates Expression of Phex, a Marker of the Mature Osteoblast. Endocrinology
140: 1192-1199
[Abstract][Full Text]
Lipman, M. L., Panda, D., Bennett, H. P. J., Henderson, J. E., Shane, E., Shen, Y., Goltzman, D., Karaplis, A. C.
(1998). Cloning of Human PEX cDNA. EXPRESSION, SUBCELLULAR LOCALIZATION, AND ENDOPEPTIDASE ACTIVITY. J. Biol. Chem.
273: 13729-13737
[Abstract][Full Text]
Econs, M. J., Francis, F.
(1997). Positional cloning of the PEX gene: new insights into the pathophysiology of X-linked hypophosphatemic rickets. Am. J. Physiol. Renal Physiol.
273: F489-F498
[Abstract][Full Text]
Candeliere, G. A., Glorieux, F. H., Prud'homme, J., St.-Arnaud, R.
(1995). Increased Expression of the c-fos Proto-Oncogene in Bone from Patients with Fibrous Dysplasia. NEJM
332: 1546-1551
[Abstract][Full Text]
Previous
